Matteo Dugo

Amadeo 42 Road
Milan, 20133, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

Journal: NPJ precision oncology

Published: February 03, 2026

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 09, 2025

Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers.

Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers.

Journal: JCO precision oncology

Published: November 14, 2025

The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms.

The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms.

Journal: Cell death and differentiation

Published: October 27, 2025

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.

Journal: NPJ breast cancer

Published: June 29, 2025

Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.

Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.

Journal: Oncotarget

Published: June 10, 2025

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 29, 2025

Correction: Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts.

Correction: Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts.

Journal: Cell death & disease

Published: March 12, 2025

From intrinsic to adaptive clusters in breast cancer.

From intrinsic to adaptive clusters in breast cancer.

Journal: Cancer cell

Published: December 19, 2024

Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023.

Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023.

Journal: JAMA network open

Published: July 19, 2024

A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors.

A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors.

Journal: The Journal of pathology

Published: May 08, 2024

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 27, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026